Biomarkers in atrial fibrillation: Investigating biologic plausibility, cause, and effect
Biomarkers in atrial fibrillation: Investigating biologic plausibility, cause, and effect
复制标题
DOI：
10.1007/s11239-005-0943-3
复制
发表时间：
2005-02-01
影响因子：
4
通讯作者：
Becker, RC
中科院分区：
文献类型：
--
作者：
Becker, RC
房颤是一种日益常见的心律失常，其患病率将在未来二十年内达到流行病的比例，其特征在于心房/心耳炎症、纤维化、重塑和内膜血栓形成。外周循环内测量的生物标志物反映了这些病理生物学事件，有证据表明凝血酶生成和活性升高、血小板活性、纤维蛋白形成、内皮损伤、炎症介质释放和纤维蛋白溶解潜力降低。不幸的是，传统生物标志物与临床事件之间的相关性充其量是弱的，其预测抗血栓剂成功治疗（预防心源性栓塞）的能力也是弱的。未来致力于研究细胞生物标志物的努力可能会提供更大的实际产量和有关房颤的发展，诊断，预后和管理的见解。
Atrial fibrillation, an increasingly common arrhythmia whose prevalence will reach epidemic proportions over the next two decades, is characterized by atrial/atrial appendage inflammation, fibrosis, remodeling, and endocardial thrombosis. Biomarkers measured within the peripheral circulation reflect these pathobiologic events with evidence of heightened thrombin generation and activity, platelet activity, fibrin formation, endocardial injury, inflammatory mediator release, and reduced fibrinolytic potential Unfortunately, the correlation between traditional biomarkers and clinical events is weak at best, as is their ability to predict successful treatment (prevention of cardioembolism) with antithrombotic agents. Future efforts devoted to the investigation of cellular biomarkers will likely provide greater practical yield and insights concerning the development, diagnosis, prognosis, and management of atrial fibrillation.